{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-051195","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.286415+00:00","generated_at":"2026-06-08T23:23:57.277276+00:00","sec_items":["4.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gyre Therapeutics dismisses auditor EisnerAmper, engages Grant Thornton; CEO and CFO exit","bullets":["EisnerAmper dismissed as auditor; Grant Thornton Zhitong engaged as new independent registered public accounting firm.","CEO Nassim Usman ceased as officer effective Oct 30, 2023; remains director; receives 12-month salary severance plus accelerated vesting.","Interim CFO Seline Miller ceased as officer effective Oct 30, 2023; receives 9-month salary severance plus accelerated vesting.","EisnerAmper’s prior reports included going-concern emphasis paragraphs related to convertible preferred stock cash settlement feature."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-051195","json":"https://secwatch.observer/filing/0001140361-23-051195.json","markdown":"https://secwatch.observer/filing/0001140361-23-051195.md","text":"https://secwatch.observer/filing/0001140361-23-051195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/ny20009756x13_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:23:57.277276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e63c382657f74a3c9d95031d1df66faa8c5ba46","claim":"GYRE THERAPEUTICS, INC. dismissed EisnerAmper LLP as its auditor.","evidence_excerpt":"(a) Dismissal of Independent Registered Public Accounting Firm Prior to the Closing Date, EisnerAmper LLP (“EisnerAmper”) served as the independent registered public accounting firm of Catalyst. On the Closing Date, following the completion of Catalyst’s audit for the year ended December 31, 2022 and the subsequent interim periods through September 30, 2023, which consisted only of the accounts of Catalyst, and the filing of Catalyst’s Annual Report on Form 10-K for the year ended December 31, 2022 and Catalyst’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Audit Committee (the “Audit Committee”) of Gyre’s board of directors dismissed EisnerAmper as Gyre’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"EisnerAmper LLP"},{"label":"Successor","value":"Grant Thornton Zhitong Certified Public Accountants LLP"}],"fact_type":"auditor_change"},{"claim_id":"6b109531e42cdcde4a6df078a8783a40910d31bf","claim":"GYRE THERAPEUTICS, INC. engaged Grant Thornton Zhitong Certified Public Accountants LLP as its auditor.","evidence_excerpt":"(b) Engagement of Independent Registered Public Accounting Firm On the Closing Date, the Audit Committee engaged Grant Thornton Zhitong Certified Public Accountants LLP (“Grant Thornton”) as Gyre’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Grant Thornton Zhitong Certified Public Accountants LLP"}],"fact_type":"auditor_change"},{"claim_id":"3cef9b6d15","claim":"Nassim Usman departed as President and Chief Executive Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer, ceased to be an officer of Gyre","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be an officer"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d9cb58c1e6","claim":"Seline Miller departed as Interim Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Seline Miller, Catalyst’s Interim Chief Financial Officer, ceased to be an officer of Gyre","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be an officer"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}